StockData
ANI Pharmaceuticals Inc logo

ANI Pharmaceuticals Inc (ANIP) stock

ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$68.55−0.58 (-0.84%)

Close on Nov 20, 2026Market cap $1.57BP/E 14.6Yield –

ANI Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

ANI Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was $172.99M, up 37.9% year over year. For fiscal 2025 it was $171.39M, up 258.7% from the year before. Over ten years it grew 27.5% a year on average. The highest annual figure on record is $171.39M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$171.39M+258.7%
FY2024Dec 31, 2024$47.78M-56.6%
FY2023Dec 31, 2023$110.09M–
FY2022Dec 31, 2022-$40.08M-5339.1%
FY2021Dec 31, 2021$765.00K-91.6%
FY2020Dec 31, 2020$9.13M-76.6%
FY2019Dec 31, 2019$39.00M-36.4%
FY2018Dec 31, 2018$61.33M+111.1%
FY2017Dec 31, 2017$29.05M+26.8%
FY2016Dec 31, 2016$22.91M+51.9%
FY2015Dec 31, 2015$15.08M-27.9%
FY2014Dec 31, 2014$20.91M–
FY2013Dec 31, 2013-$5.68M–
FY2012Dec 31, 2012-$429.00K–
FY2011Dec 31, 2011-$48.59M–
FY2010Dec 31, 2010-$40.16M–
FY2009Dec 31, 2009-$18.60M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$53.62M-25.3%
Q1 FY2026Mar 31, 2026$52.30M+60.8%
Q4 FY2025Dec 31, 2025$29.12M+116.3%
Q3 FY2025Sep 30, 2025$37.95M+395.3%
Q2 FY2025Jun 30, 2025$71.80M+453.8%
Q1 FY2025Mar 31, 2025$32.52M+137.6%
Q4 FY2024Dec 31, 2024$13.47M-68.3%
Q3 FY2024Sep 30, 2024$7.66M-74.8%
Q2 FY2024Jun 30, 2024$12.97M-28.5%
Q1 FY2024Mar 31, 2024$13.69M-28.2%
Q4 FY2023Dec 31, 2023$42.46M–
Q3 FY2023Sep 30, 2023$30.43M+2534.6%
Q2 FY2023Jun 30, 2023$18.13M–
Q1 FY2023Mar 31, 2023$19.08M–
Q4 FY2022Dec 31, 2022-$7.54M–
Q3 FY2022Sep 30, 2022$1.16M–
Q2 FY2022Jun 30, 2022-$12.81M–
Q1 FY2022Mar 31, 2022-$20.89M-204.6%
Q4 FY2021Dec 31, 2021-$12.54M–
Q3 FY2021Sep 30, 2021-$5.97M–
Q2 FY2021Jun 30, 2021-$691.00K-103.4%
Q1 FY2021Mar 31, 2021$19.97M+11578.4%
Q4 FY2020Dec 31, 2020-$7.82M-352.2%
Q3 FY2020Sep 30, 2020-$3.38M-116.7%
Q2 FY2020Jun 30, 2020$20.16M+548.1%
Q1 FY2020Mar 31, 2020$171.00K-98.6%
Q4 FY2019Dec 31, 2019$3.10M-88.2%
Q3 FY2019Sep 30, 2019$20.27M+191.8%
Q2 FY2019Jun 30, 2019$3.11M-58.6%
Q1 FY2019Mar 31, 2019$12.52M-39.4%
Q4 FY2018Dec 31, 2018$26.23M+112.2%
Q3 FY2018Sep 30, 2018$6.95M-52.4%
Q2 FY2018Jun 30, 2018$7.51M–
Q1 FY2018Mar 31, 2018$20.65M+370.3%
Q4 FY2017Dec 31, 2017$12.36M+15.6%
Q3 FY2017Sep 30, 2017$14.60M–
Q2 FY2017Jun 30, 2017-$2.30M–
Q1 FY2017Mar 31, 2017$4.39M–
Q4 FY2016Dec 31, 2016$10.69M–
Q3 FY2016Sep 30, 2016-$5.00K–

More ANI Pharmaceuticals figures

See a number that looks wrong?